A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 14 Dec 2018 Planned End Date changed from 24 Apr 2020 to 27 Mar 2020.
- 14 Dec 2018 Planned primary completion date changed from 24 Apr 2020 to 27 Mar 2020.
- 07 Oct 2018 Status changed from recruiting to active, no longer recruiting.